In another study, Glypian-3 (GPC3) was shown to be a suitable target for Chimeric antigen receptor (CAR) therapy in HCC, and therapeutic approaches using GPC3-targeted antibodies or peptide vaccines are safe (65). The gene discussed is GPC3; the disease is hepatocellular carcinoma.